cytospireadmin3467, Author at Cytospire

About cytospireadmin3467

This author has not yet filled in any details.
So far cytospireadmin3467 has created 5 blog entries.

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer

Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and LifeArc Ventures

Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancercytospireadmin34672026-05-05T13:31:42+00:00

AACR Annual Meeting, San Diego

16-22 April, 2026

AACR Annual Meeting, San Diegocytospireadmin34672026-05-05T14:40:52+00:00

Hanson Wade Bispecific Summit, London

7-9 July, 2026

Hanson Wade Bispecific Summit, Londoncytospireadmin34672026-05-05T14:41:43+00:00

Jefferies Healthcare Conference, London

16-19 November, 2026

Jefferies Healthcare Conference, Londoncytospireadmin34672026-05-05T14:42:42+00:00

Cytospire Therapeutics will be attending the J.P. Morgan Healthcare Conference, San Francisco

13-16 January, 2025

Cytospire Therapeutics will be attending the J.P. Morgan Healthcare Conference, San Franciscocytospireadmin34672026-04-28T13:34:27+00:00